Results 191 to 200 of about 562,936 (248)
Accomplishments of "Old-Fashioned" Electron Microscopy in the Period of Dominance of Immunofluorescent Methods. [PDF]
Morozov YM, Rakic P.
europepmc +1 more source
WIN55,212-2 attenuates intestinal fibrosis in a DSS-induced mouse model. [PDF]
Misztal Z +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Pharmacology and Experimental Therapeutics, 1999
Two subtypes of the cannabinoid receptor (CB1 and CB2) are expressed in mammalian tissues. Although selective antagonists are available for each of the subtypes, most of the available cannabinoid agonists bind to both CB1 and CB2 with similar affinities.
Ruth Ross +2 more
exaly +4 more sources
Two subtypes of the cannabinoid receptor (CB1 and CB2) are expressed in mammalian tissues. Although selective antagonists are available for each of the subtypes, most of the available cannabinoid agonists bind to both CB1 and CB2 with similar affinities.
Ruth Ross +2 more
exaly +4 more sources
Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor [PDF]
Human cannabinoid type 1 (CB1) G-protein coupled receptor is a potential therapeutic target for obesity. The previously predicted and experimentally validated ensemble of ligand-free conformations of CB1 [Scott, C. E. et al. Protein Sci.
Ravinder Abrol +2 more
exaly +8 more sources
CNS & Neurological Disorders - Drug Targets, 2011
Cannabinoids are antinociceptive in animal models of acute pain, tissue injury and nerve injury induced nociception and act via their cognate receptors, cannabinoid receptor 1 and 2. This review examines the underlying biology of the endocannabinoids and behavioural, neurophysiological, neuroanatomical evidence supporting the notion of pain modulation ...
Rashmi Talwar, V. Potluri
semanticscholar +3 more sources
Cannabinoids are antinociceptive in animal models of acute pain, tissue injury and nerve injury induced nociception and act via their cognate receptors, cannabinoid receptor 1 and 2. This review examines the underlying biology of the endocannabinoids and behavioural, neurophysiological, neuroanatomical evidence supporting the notion of pain modulation ...
Rashmi Talwar, V. Potluri
semanticscholar +3 more sources
Aminopyrazine CB1 receptor inverse agonists
Bioorganic and Medicinal Chemistry Letters, 2008A series of 5,6-diaryl-2-amino-pyrazines were prepared and found to have antagonist-like properties at the CB1 receptor. Subsequent SAR studies optimized both receptor potency and drug-like properties including solubility and Cytochrome-P450 inhibition potential.
David J Wustrow +2 more
exaly +3 more sources
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists
Novel 3-(1H-indol-3-yl)-1,2,4-oxadiazoles and -thiadiazoles were synthesized and found to be potent CB1 cannabinoid receptor agonists. The oral bioavailability of these compounds could be dramatically improved by optimization studies of the side chains ...
Takao Kiyoi
exaly +5 more sources
Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonists
Bioorganic and Medicinal Chemistry Letters, 2007Optimization of the biological activity for 5,6-diarylpyridines as CB1 receptor inverse agonists is described. Food intake and pharmacokinetic evaluation of 3f and 15c indicate that these compounds are effective orally active modulators of CB1.
Alison M Strack +2 more
exaly +3 more sources
Acute effects of partial CB1 receptor agonists on cognition - A meta-analysis of human studies.
Progress in Neuro-psychopharmacology and Biological Psychiatry, 2020BACKGROUND Impairment in cognition is frequently associated with acute cannabis consumption. However, some questions remain unanswered as to which deficits are most prominent and which demographic groups are most vulnerable. METHODS A literature search
Simon Zhornitsky +5 more
semanticscholar +1 more source

